I. Basic Information

• Product Name: Crizotinib

• CAS Number: 877399-52-5

• Molecular Formula: C21H22Cl2FN5O

• Molecular Weight: 450.34

II. Physical Properties

• Appearance: White to pale yellow powder

• Melting Point: 192°C

• Boiling Point: 599.2±50.0°C (predicted)

• Density: 1.47±0.1 g/cm3 (predicted), alternatively 1.5±0.1 g/cm3 (reported)

• Solubility: Soluble in DMSO (up to 25 mg/mL with heating) or ethanol (up to 25 mg/mL with heating)

• pKa: 9.81±0.10 (predicted)

III. Pharmacological Properties

• Mechanism of Action: Crizotinib is an orally administered small molecule drug that effectively inhibits the activity of tyrosine kinases such as ALK (anaplastic lymphoma kinase), c-MET, and ROS1. It selectively binds to the ATP-binding site of these tyrosine kinases, blocking their phosphorylation and downstream signaling pathways, thereby inhibiting the growth and invasion of tumor cells.

• Indications: Primarily used for the treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Additionally, it is indicated for patients with metastatic NSCLC harboring ROS1 mutations.